MiNK Reports Q3 Results, Sees First Product Revenue
MiNK Therapeutics generated its first pre-commercial revenue from the aggregation therapy agenT-797 during the third quarter. The company highlighted the advancement of its randomized ARDS trial and selection for a major ARPA-H program, which could drive future growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed